Results 181 to 190 of about 89,537 (296)

JAK inhibitor tofacitinib alleviates secretory dysfunction and Th17/Treg imbalance in a Sjögren's disease murine model. [PDF]

Ann Med
Lin Y, Ou Y, Su J, Xu J, Liu C, He K, Zhou L, Wu D, Chen J.   +8 more
europepmc   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

RNA-seq Transcriptomic Characterization of JAK Inhibitor-Resistant Cell Models

reservedThis study analysed the transcriptome of cellular models of Myeloproliferative Neoplasms (MPNs) resistant to the JAK inhibitor Ruxolitinib.
ANTOLINI, FEDERICO
core  

A multicentered retrospective cohort study comparing JAK inhibitor therapies in moderate-to-severe ulcerative colitis. [PDF]

Crohns Colitis 360
Kumar A, Baxter J, Rimmer P, Noble B, Bower J, Makki MU, Hatta A, Chikhlia A, Cheesbrough J, Disney B, Muir J, Karova M, Butterworth J, Sagar N, Al-Talib I, Nahal J, Ali N, Sagar V, Varyani F, Smith S, Bourne S, Hsu YK, Eltahir A, de Silva S, Harvey P.   +24 more
europepmc   +1 more source

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

Molecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain, Yann Le Page, Frédéric Percevault, Emmanuelle Becker, Luc Negroni, Almudena Fernandez, Marta Cantero, Diego Muñoz‐Santos, Lluís Montoliu, Cyrille Garnier, Michael Primig   +10 more
wiley   +1 more source

Potential benefits of JAK inhibitor therapy in Blau syndrome: a case report. [PDF]

Front Immunol
Wang Y, Yu XJ, Zhang Z.
europepmc   +1 more source

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

Molecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu, Xixi Lin, Emil Mladenov, Veronika Mladenova, Jürgen Thomale, Ali Sak, Yao Wang, Yunxuan Deng, Eleni Gkika, Martin Stuschke, George Iliakis   +10 more
wiley   +1 more source

Preclinical models of hepatosplenic γδ T-cell lymphoma with an activating STAT5B mutation display sensitivity to JAK inhibitor upadacitinib. [PDF]

Hemasphere
Aung MMK, Schönefeldt S, Pfalz-Kraupp S, Wais T, Suske T, Zahma S, Franz S, Müllebner A, Feurstein G, Wagner C, Eder T, Pemovska T, Agreiter C, Pichler A, Staber PB, Hofer M, Steinborn R, Strohmer SV, Simonitsch-Klupp I, Bauer M, Wilfer A, Weber T, Potdar S, Aittokallio T, Jungherz D, Müller TA, List J, Gotthardt D, Grebien F, Bekiaris V, Herling M, Moriggl R, Neubauer HA.   +32 more
europepmc   +1 more source

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib. [PDF]

Future Oncol
Vachhani P, Yacoub A, Rampal R, Bradley T, Harrison C, Jain T, Kuykendall A, Palandri F, Mascarenhas J, Al-Ali H, Passamonti F, Rothbaum W, Verstovsek S, Heidel FH.   +13 more
europepmc   +1 more source